ALBT: Avalon GloboCare Corp. Stock

by  •  • Comments Off on ALBT: Avalon GloboCare Corp. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 6.18
Enterprise Value ($M) 36.47
Book Value ($M) 7.10
Book Value / Share 4.30
Price / Book 0.87
NCAV ($M) -10.65
NCAV / Share -6.45
Price / NCAV -0.58

Profitability (mra)
Return on Invested Capital (ROIC) -0.47
Return on Assets (ROA) -0.39
Return on Equity (ROE) -1.31

Liquidity (mrq)
Quick Ratio 0.23
Current Ratio 0.23

Balance Sheet (mrq) ($M)
Current Assets 3.24
Assets 20.99
Liabilities 13.88
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.49
Operating Income -4.93
Net Income -7.90
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -4.97
Cash from Investing -0.10
Cash from Financing 7.64

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-31 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-19 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-31 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-04-15 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-11 2,103 24,738 8.50
2025-04-10 20,749 115,696 17.93
2025-04-09 12,087 40,965 29.51
2025-04-08 2,133 6,385 33.41
2025-04-07 2,874 22,520 12.76

(click for more detail)

Similar Companies
AIMD – Ainos, Inc. AKAN – Akanda Corp.
AKBA – Akebia Therapeutics, Inc. ALDX – Aldeyra Therapeutics, Inc.
ALGS – Aligos Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io